Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Decrease in Short Interest
by Doug Wharley · The Cerbat GemFresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 28,906 shares, a decline of 51.7% from the September 15th total of 59,859 shares. Based on an average daily volume of 160,909 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.
Analyst Ratings Changes
A number of equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat, the stock has an average rating of “Buy”.
Check Out Our Latest Stock Report on FSNUY
Fresenius SE & Co. Stock Performance
Shares of OTCMKTS:FSNUY traded up $0.25 during trading on Wednesday, hitting $12.33. 243,973 shares of the stock traded hands, compared to its average volume of 163,425. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. The company has a market cap of $27.78 billion, a price-to-earnings ratio of 15.61 and a beta of 0.60. The company has a fifty day moving average price of $13.09 and a two-hundred day moving average price of $12.35. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $33.93.
Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. The company had revenue of $6.91 billion during the quarter, compared to analysts’ expectations of $6.65 billion. As a group, equities analysts predict that Fresenius SE & Co. will post 1.08 EPS for the current year.
About Fresenius SE & Co.
Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.
Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.
Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.